Navigation Links
Gene Network Sciences Announces Drug Development Collaboration with Biogen Idec
Date:10/1/2008

CAMBRIDGE, Mass., Oct. 1 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced that it has entered into an agreement with Biogen Idec under which GNS will use its proprietary REFS(TM) software platform to process clinical data provided by Biogen Idec to identify targets and biomarkers in inflammation. A forward simulation model generated directly from the Biogen Idec data will be licensed to Biogen Idec at the conclusion of this project. Financial terms of the agreement were not disclosed.

GNS employs massively parallel supercomputers to probe vast amounts of raw human biological data to discover new insights into the biological causes of human disease, and new opportunities for diagnosis and treatment. Under this agreement, GNS will use its REFS(TM) (Reverse Engineering/Forward Simulation) platform to transform genetic, genomic, and clinical data provided by Biogen Idec to generate and score billions of hypotheses to discover new drug targets and biomarkers rapidly.

"Our proprietary technology is capable of taking raw 'omic' data and running billions of calculations in a short period of time to find potential biomarkers and promising drug targets that could lead to more effective patient treatments," said Colin Hill, CEO of GNS. "It is the value and speed of our REFS(TM) technology and the potential it offers to the Biogen Idec drug development program that forged our partnership."

About REFS(TM)

Reverse Engineering/Forward Simulation (REFS(TM)) is a technology that systematically turns multiple layers of biologically relevant data into an unprecedented view of human biology and disease as a "whole." REFS(TM) begins with raw biological data (genetic, genomic, epigenetic, proteomic, metabolomic and environmental) and rapidly performs billions upon billions of calculations to determine how the molecules interact with one another in the complete system (Reverse Engineering). These computer-assembled models are then queried rapidly through billions of in silico experiments (Forward Simulation) to discover the highest-impact molecular targets for the disease being studied and the corresponding efficacy and toxicity markers related to specific drug treatments. These findings are then tested in both the laboratory and the clinic, enabling a faster, more focused and more effective drug discovery and development process.

About Gene Network Sciences

Founded in 2000, Gene Network Sciences (http://www.gnsbiotech.com/) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data without any a priori knowledge. Headquartered in Cambridge, Massachusetts, GNS uses its REFS(TM) (reverse engineering and forward simulation) technology in pharmaceutical and clinical settings to rapidly turn complex and heterogeneous data sets into cell and organ-level computer models of disease biology, drug efficacy and drug safety. These models simulate mechanisms of disease and the clinical performance of drug candidates. By discovering how and why specific drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.

For more Information, please contact:

Lynn Blenkhorn Thomas Neyarapally

Feinstein Kean Healthcare Gene Network Sciences, Inc.

508-851-0930 617-494-0492

Lynn.blenkhorn@fkhealth.com tneyarapally@gnsbiotech.com


'/>"/>
SOURCE Gene Network Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Access Innovations Provides Support Services for Agis Network
2. Womens World Banking Welcomes New Network Member From Tunisia
3. Internet TV Network for Personal Trainers is Launched
4. Quality Innovators to Network in Atlanta Sept. 19-21: Learn from Those Who Got It Right
5. Guardians Dental Network Experiences Double-Digit Growth
6. Chronic infection persists by targeting stromal cell network in lymphoid organs
7. The American Pain Foundation (APF) and The HealthCentral Network Collaborate to Develop Enhanced Internet Resources for People with Pain
8. Blue Care Network of Michigan Earns National Leadership Award for Chronic Disease Management
9. AT&T Offers Network Industry-First RFID Solution for Health Care Organizations
10. AT&T Establishes New Network Services for Leading Medical Liability Insurer
11. Portico Systems to Share Provider Network Management Best Practices at Institute for International Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: